Biopharma Insights
Leqembi, Donanemab and Tofersen: The End of the Journey or the First Step on the Road to Reversing Neurodegeneration?
Dr. Peter Hamley, Chief Scientific Officer at Samsara Therapeutics, explores whether developments in therapeutics for neurodegenerative diseases are truly disease modifying or addressing the symptoms of a deeper problem. Read more
16 Aug 2023
R&D revolution: A new paradigm of sourcing and landscaping for the pharma industry
Dr Robin Knight, Co-Founder & Co-CEO of IN-PART, discusses the emerging importance of outsourcing landscaping activities within the pharmaceuticals industry and the benefits of adopting an openly innovative approach that pools sources of innovation. Read more
12 Jul 2023
Enhancing Biotherapeutic Properties with Cell-Line Engineering
Neha Mishra, Ph.D, Senior Scientist Bioproduction at Revvity explores enhancing biotherapeutic properties with cell-line engineering. Read more
30 Jun 2023
Cell line development strategies fit for a new era of Bispecific Antibodies
Nicole Wakes, Senior Director Cell Line Development, and Simon Keen, Vice President Cell Line Development at Abzena, outline the strategies to overcome the challenges of developing BsAbs under increasing pressure for speed. Read more
26 Jun 2023
Science and tech combine to deliver cancer vaccine innovation
Scientific and technological innovation is accelerating the development of effective cancer vaccines, report Drs. Daina Vanags, Cori Gorman and Christian K. Schneider of Biopharma Excellence. Read more
12 Apr 2023
Leveraging RWE early is critical for emerging biopharma companies
Barbara Arone, vice president, real world solutions, IQVIA, examines the ways biotech and emerging biopharma companies can effectively apply real world evidence (RWE) early in the product lifecycle while staying within their resource limits. Read more
3 Mar 2023
PCI Pharma Services
PCI Pharma Services invests over $365 million in EU and US facilities
PCI Pharma Services, (“PCI”) a global contract development and manufacturing organisation (CDMO) focused on biopharma’s most complex therapies, is investing more than $365 million in infrastructure. Read more
27 Sep 2024
ART-ur / Shutterstock.com
Antabio completes Phase 1 clinical study of MEM-ANT3310 for severe hospital infections
Antabio has announced that it has completed the Phase 1 clinical trial for MEM-ANT3310 in healthy volunteers. Read more
3 Sep 2024
AskBio
AskBio initiates recruitment to its Phase 2 Parkinson’s Disease trial
AskBio a gene therapy company wholly owned and independently operated as a subsidiary of Bayer, has announced initiation of recruitment to REGENERATE-PD, a Phase 2 clinical study assessing efficacy and safety of AB-1005. Read more
26 Jun 2024
Smart Calendar/Shutterstock
Mapping the counterfeit and diversion epidemic in the pharma industry
Stephan Von Schilcher, global strategic account manager at Systech, discusses the repercussions of counterfeit drug epidemic on patients and what pharma companies must to combat the problem. Read more
9 Oct 2024
Pharmaceutical Insights + Pharmaceutical Manufacturing Insights
Solutum
What Solutum's collab with pester pac means for pharma packaging
In an interview following FACHPACK, editor Rebekah Jordan caught up with Sharon Barak, president and co-founder of Solutum, on the reasons behind their partnership with pester pac and the wider pharma packaging challenges it addresses. Read more
4 Oct 2024
fazon/Adobe Stock
Behind the scenes: 35 years of CPHI
EPM got a sneak preview of what to expect at CPHI's 35th anniversary next week from Tara Dougal, brand and content director at CPHI Milan. Read more
3 Oct 2024
CPHI
BLA and Tides to surpass small molecules, CPHI Milan report predicts
The CPHI Annual Industry Survey reveals that the pharma sector is on the cusp of a major shift, with approvals for complex molecules expected to outpace those for small molecules for the first time. Read more
3 Oct 2024
FOTOGRIN/Shutterstock
Enhancing pharma innovation with biofermentation and synthesis
David Blanco, Industrial BD & CDMO director, Suanfarma, shares how the pharma industry can enhance innovation by combining biofermentation and chemical synthesis, while highlighting the importance of technology transfer for implementation of both. Read more
3 Oct 2024
Impress Designers/Adobe Stock
Q&A: Quotient Sciences innovates personalised paediatric therapies
Ahead of CPHI Milan, EPM spoke to Thierry Van Nieuwenhove, CEO of Quotient Sciences, to explore how the company is innovating to meet the growing demand for personalised medicine through AI, partnerships and meeting sustainability goals. Read more
2 Oct 2024
Sponsored Content
TierneyMJ / Shutterstock.com
Why Pharmaceutical Industry Needs a Digital Content Factory (DCF)?
Modern pharma brands pursue a higher degree of content personalisation to engage with diverse audiences. This means tighter deadlines, higher workloads, and a greater demand for skilled content creators than ever before. Read more
